ABL Bio Completes 140 Billion KRW Paid-in Capital Increase

ABL Bio, a company specializing in bispecific antibodies, announced on the 11th that it has completed the payment for a third-party allotment capital increase worth 140 billion KRW.

Accordingly, ABL Bio will issue 5,778,196 shares of non-redeemable convertible preferred stock (CPS) to KDB Industrial Bank, Atinum Investment, Intervest, Hana Financial Group, and Company K Partners, which will be subject to a one-year lock-up period at the Korea Securities Depository.

The convertible preferred stock will not be listed until the lock-up period ends and before the conversion rights are exercised.

This content was produced with the assistance of AI translation services.